We previously demonstrated in vitro that inhibiting the biological pathways of the small GTPase Rho radiosensitizes the human glioma U87 cell line. The aim of this study was to determine if Rho might be involved in the control of in vivo radiosensitivity altogether by controlling cellular radioresistance and by modifying tumor microenvironment. We demonstrate here that the in vivo induction of the dominant negative of Rho, RhoBN19, in U87 xenografts induces a significant decrease of tumor cell survival after irradiation more important than the one we previously observed in vitro. This in vivo increased effect of RhoBN19 expression is due to the improvement of the tumor oxygenation associated with a significant decrease of the vessel density and of the metalloproteinase 2 (MMP2) expression. Moreover, in vitro RhoBN19 expression in U87 cells leads to the inhibition of MMP2 activity. Our results demonstrate for the first time that inhibiting Rho pathways modifies the in vivo radiosensitivity of human glioma cells by controlling intrinsic radioresistance, hypoxia and angiogenesis. These data strongly suggest that Rho should be a major determinant of cellular resistance to ionizing radiation.
Introduction
The growth of solid tumors is largely dependent on the development of its own vascular system for adequate oxygen and nutrient delivery. The tumor vasculature is induced from existing host vessels by angiogenic factors secreted by tumor cells or surrounding tissues. However, these newly formed vessels are less functional than the normal ones leading to a poorer delivery of oxygen and nutrients to tumors. The presence of these hypoxic regions is associated, in solid tumors, with a more malignant tumor phenotype. Such regions are less sensitive to the killing effects of the different therapies used in clinical oncology, especially of radiotherapy, resulting in a worse prognosis. Indeed, a poorer clinical outcome after radiotherapy has been described in lessoxygenated tumors, in particular in sarcoma, head and neck and cervix carcinoma (Hockel et al., 1994; Kohl et al., 1995; Brizel et al., 1996 Brizel et al., , 1997 . Glioblastoma present a catastrophic prognosis due to a local recurrence despite surgery, radiotherapy and chemotherapy. They are one of the most vascularized human cancers, and the formation of tumor-specific vessels occurs early at the onset of tumor growth. These very aggressive tumors contain large regions of hypoxia, suggesting that a treatment able to increase tumor oxygenation might regulate radiosensitivity of glioma.
One of our recent studies demonstrated that a new class of compounds, the farnesyltransferase inhibitors (FTI), could present an antihypoxia effect associated with radiosensitization (Cohen-Jonathan et al., 2001) . FTI were initially synthesized to block the Ras oncogenic processing. Indeed, FTI inhibit spontaneous tumors in ras transgenic mice (Kohl et al., 1995; Barrington et al., 1998) , as well as certain human tumor xenografts in nude mice (Kohl et al., 1994; Sun et al., 1995) . As Ras has been involved in a radioresistant phenotype (McKenna et al., 1990 (McKenna et al., , 1991 , the effect of FTI as a radiosensitizer has been studied. Bernhard et al. (1996) have shown that FTI treatment radiosensitizes Ha-ras-transformed rat embryo fibroblasts and human tumor cell lines expressing activated Ha-ras in vitro (Bernhard et al., 1998) . We have demonstrated a radiosensitization of tumors with mutated H-Ras by FTI in vivo (Cohen-Jonathan et al., 2000) , and further shown that part of this in vivo effect was due to a reduction of hypoxia in tumors expressing H-ras mutation (Cohen-Jonathan et al., 2001) . Nevertheless, these last results do not exclude the possibility that a farnesylated protein other than Ras could be the target of FTI in vivo in the modulation of the hypoxia. In fact, we have recently shown that FTI treatment induces a radiosensitization of radioresistant HeLa cells transfected by the cDNA encoding for the 24 kDa isoform of the FGF-2, whereas these cells do not express a mutated H-ras (Cohen-Jonathan et al., 1999). The same radiosensitizer effect by FTI treatment was observed in the radioresistant human U87 glioblastoma cell line that expresses wild-type Ras and FGF-2 . Moreover, we have demonstrated in these two cellular models that Rho, but not Ras, is implicated in the control of the radioresistance pathway, suggesting that Ras is not the only target of the FTI radiosensitizer effect (Ader et al., 2002; Delmas et al., 2002) . The Rho proteins belong to a family of small GTPases that regulate cytoskeletal actin, focal adhesion formation, cell adhesion signaling, receptor-mediated internalization, motility, transformation, invasion, survival and transcription (Lebowitz et al., 1997; Van Aelst and D'Souza-Schorey, 1997) , and include members that are geranylgeranylated or gernanylgeranylated and farnesylated like RhoB (Adamson et al., 1992) . RhoB is an early gene that is rapidly induced by UV radiation and DNA-damaging agents (Fritz and Kaina, 1997) . For our part, we have recently shown that the expression of RhoB, but not Rho A, in radiosensitive cells increases cell survival after irradiation of these cells, suggesting that RhoB might control a biological pathway promoting cellular resistance to ionizing radiation (Ader et al., 2002) . Taken together, these data suggest that Rho might be involved in the control of tumor radiosensitivity by controlling intrinsic cellular radioresistance and by modifying tumor microenvironmental oxygen homeostasis. The aim of this study was to test this hypothesis.
For this, we determined the effect of RhoBN19 expression on in vivo glioma radiosensitization. We demonstrate here that expressing this Rho dominant negative in human glioma xenografts induces a more important radiosensitizer effect in vivo than in vitro due to the control by Rho pathways of the tumor oxygenation.
Materials and methods

Materials
DMEM, calf serum, G418 and all other culture reagents were purchased from GIBCO Life Technologies SARL (Cergy Pontoise, France). Pathogen-free NMRi Nu/Nu nude mice were obtained from Janvier (France). Dexamethasone from Qualimed Laboratories (France), the fibronectin, the gelatin, the DNase, collagenase IX and protease were purchased from Sigma (Sigma, France). Horseradish peroxidase-labeled goat anti-rabbit IgG anti-mouse, nitrocellulose and nonfat dried milk protein were from Biorad (Ivry/Seine, France); ECL system and Hyperfilm MP were from Amersham (les Ulis, France). Mice were irradiated with a clinical Cobalt 60 machine (Theratronics 1000, AECL, Ottawa, Canada). Micro-osmotic pumps were from Alza Corporation, Palo Alto, CA, USA). Antibody anti-CD31 was from Dako (Trappes, France) and Envision and monoclonal anti MMP2 from R and D systems (Abingdon, UK). Anti-EF5 was provided by Dr Koch (University of Pennsylvania, USA).
Cell culture
Human glioblastoma U87 cells were routinely maintained in DMEM supplemented with 10% calf serum at 371C in 5% CO 2 -humidified incubators and subcultured weekly. U87RhoBN19 cells were generated by transfecting U87 cells with the dominant negative of RhoB, RhoBN19 . U87 and U87RhoBN19 were maintained in DMEM supplemented with 10% calf serum and 5 mg/ml G418.
Fibronectin was diluted in phosphate-buffered saline (PBS) at 100 mg/ml and plated, and then was incubated overnight at 41C. The remaining fluid was then aspirated. After a wash of the fibronectin with PBS, glioblastoma cell lines resuspended in serum-free DMEM medium were plated at 10 7 cells in 100 mm diameter dishes coated with fibronectin and then incubated at 371C. At the time of plating, cells were treated by 25 nM dexamethasone for 72 h. At 72 h after plating, the conditioned medium was collected, centrifuged and stored at À201C.
Transfection with RhoBN19 cDNA pGRE5.2 plasmid provided by Dr White (Mader and White, 1993) was designed to induce high levels of mRNA driven by five glucocorticoid response elements placed upstream of the cloning site. To create pGRE5-2/RhoBN19 recombinant, RhoBN19 cDNA (provided by Dr B. Olofsson, Gif-surYvette, France) was cloned as a HindIII-EcoR1 insert into the cloning site of the pGRE5.2 plasmid. Ten mg of pGRE5.2/ RhoBN19 and 1 mg of PINA plasmid carrying the cDNA encoding for neomycin resistance (Mader and White, 1993) were cotransfected into glioma cells using Lipofectamin (Gibco, France) according to the manufacturer's instructions. Selection was initiated 48 h later by incubating cells in fresh medium containing 1 mg/ml neomycine. In vitro induction of RhoB dominant negative was realized by incubating cells for 48 h with 25 nM dexamethasone .
Tumor xenograft generation and in vivo RhoBN19 induction
Mice were housed aseptically. At 5-7 weeks of age, mice were inoculated by s.c. injection into the hind flank with 1 Â 10 6 U87 or U87RhoBN19 cells resuspended in serumfree DMEM medium. Once the U87RhoBN19 xenografts were generated, RhoBN19 was induced in vivo by treating the mice for 6 days with dexamethasone delivered subcutaneously by continuous micro-osmotic pump infusion at a concentration of 50 mg/24 h.
Analysis of RhoBN19 expression
Tumor xenografts were lysed by Polytron (Kinematica, Switzerland) on ice in Trizol reagent and total RNA was extracted as described by the manufacturer (Life Technology, France). RT-PCR was then performed using the One Step kit as described by the manufacturer (Qiagen, France) to amplify RhoBN19 cDNA and the b-globin to verify the quality of the RT-PCR reaction. For RhoBN19 amplification, the primers used covered the first 20 base pairs of the coding sequence of RhoBN19 for the sense primer and a sequence in the polylinker site of pGRE5.2 for the antisense.
In vivo clonogenic assay
Animals were assigned randomly to treatment groups when tumors attained a volume of 200-300 mm 3 . Dexamethasone was administered s.c. by continuous micro-osmotic pump infusion as described previously for 6 days prior to irradiation at a dose of 50 mg per day. Mice were whole-body irradiated at a dose of 5 Gy under anesthesia. Irradiation was performed after 6 days of dexamethasone infusion. Control animals were anesthetized and sham irradiated. Within 30 min after irradiation, animals were killed by cervical dislocation. Tumors were then excised, minced and dissociated for 30 min at 371C in Hanks' balanced salt solution containing 166 U/ml collagenase XI, 0.25 mg/ml protease and 225 U/ml DNase. Cells were recovered by straining through an 80 mm mesh and centrifuging at 500 g and were resuspended in culture medium. Cells were counted by hemocytometer using trypan blue to determine viability, and then the counts were verified by Coulter counter analysis. The survival fraction at 5 Gy was then studied by the limited dilution cloning as already described (Bernhard et al., 1998) . Cells were plated in 96-well dishes in a volume of 200 ml and cultured for 8-15 days, after which the plates were scored for the presence of colonies. Linear regression analysis was performed on the natural log of negative wells with the origin as the initial point of the line. Survival fraction at 5 Gy (SF5) was defined as the slope of the line obtained from cell cultures from irradiated mice divided by the slope of the line obtained from cultures coming from the sham-irradiated animals.
Detection of hypoxia and vessels
After completion of the 6 days of dexamethazone administration, mice were injected with 10 mM pentafluorinated 2-nitroimidazole (EF5) in 0.9% saline i.v. (0.01 ml/g body weight), followed by an equal volume i.p. injection 30 min later. At 3 h after the first EF5 injection, mice were euthanized and tumors were excised. Tumors were then immediately frozen. Frozen tissue sections (5 mm) were cut from the tumor onto poly-L-lysine-coated slides, fixed in 4% paraformaldehyde for 1 h, and then rinsed. For the vessel detection, the samples were washed and blocked for 30 min at room temperature. The sections were then incubated for 90 min with rat anti-mouse CD31 (platelet/endothelial cell adhesion molecule 1) monoclonal antibody (Pharmingen International) (1/100). After a rinse, an endogenous peroxidase block was applied for 15 min. Secondary polymer from the Envision Kit (Dako, France) was applied for 30 min at room temperature. Visualization of CD31 was realized by diaminobenzidine substrate. After rinsing in water, slides were lightly counterstained with hematoxylin, dehydrated and mounted. For EF5 detection of hypoxia, slides were stained after fixation and rinsing with Cy3-conjugated ELK-51 (75 mg/ml), a mouse monoclonal antibody to EF5 (Fenton et al, 1999) . Stained sections were then mounted with Vectashield (Vector Laboratories Inc., Burlingame, CA, USA), viewed on a Zeiss microscope through immersion lens and then photographed. The density of the vessel staining was determined using the Qwin software (Leica, France) by quantifying the ratio of the anti-CD31 stained surface versus the total surface of the slice. Quantification was performed on at least three different xenografts in each group of treatment. Five fields were randomly chosen in each slice.
Immunohistochemistry analysis of MMP2 expression
Immunohistochemistry was performed on frozen tissue sections (5 mm) fixed in 4% paraformaldehyde for 1 h and then rinsed. The sections were then incubated for 90 min with mouse anti-human MMP2 (2 mg/ml). After a rinse, an endogenous peroxidase block was applied for 15 min. Secondary polymer from the Envision Kit was applied for 30 min at room temperature. Visualization of MMP2 was realized by diaminobenzidine substrate. After rinsing in water, slides were lightly counterstained with hematoxylin, dehydrated and mounted. Stained sections were then mounted with Vectashield (Vector Laboratories Inc., Burlingame, CA, USA).
Gelatin zymography
U87RhoBN19 or U87 cells were plated as previously described on fibronectin-coated 100 mm diameter dishes and treated for 72 h with dexamethasone. The conditioned medium was obtained from 10 7 cells and subjected to SDS-PAGE through 7.5% polyacrylamide gels copolymerized with 16.7 mg/ml gelatin (Sigma, France). Gels were washed with 2% Triton X-100, rinsed with 50 mM Tris and incubated overnight at 371C in 50 mM Tris, 5 mM CaCl 2 , 200 mM NaCl, 1% Triton X-100 and 0.02% sodium azide. Gels were fixed and stained with 0.2% Coomassie blue. After destaining, gelatinolytic signals were analysed (Deb et al., 1999) .
Results
RhoBN19 expression induces a radiosensitization of U87 xenografts
To investigate if RhoBN19 expression could present a radiosensitizer effect in vivo, we first generated human glioma xenografts from U87 cells transfected with RhoBN19 cDNA downstream from a glucocorticoid inducible promotor (U87RhoBN19 cells) . We first determined the conditions of dexamethasone treatment to induce RhoBN19 expression in vivo. For this, RhoBN19 induction was followed by analysing the presence of RhoBN19 mRNA in xenografts using RT-PCR. As shown in Figure 1a , the in vivo induction Glioma oxygenation by inhibition of Rho I Ader et al of RhoBN19 was obtained when the animals were treated with dexamethasone delivered s.c. by microosmotic pump continuously (50 mg/24 h) for 6 days. This treatment protocol was therefore used as the basis for further in vivo studies.
To analyse the effect of RhoBN19 expression on xenograft radiosensitivity, we performed tumor cell colony formation assays to quantify tumor cell clonogenic potential after RhoBN19 induction in U87RhoBN19 xenografts. The clonogenicity of tumors was compared after irradiation for dexamethasone-treated mice or control mice bearing U87RhoBN19 xenografts. No significant reduction in plating efficiency was seen in cells isolated from U87RhoBN19 xenografts in mice treated by dexamethasone alone (data not shown). Treating mice with dexamethasone did not modify the surviving fraction after 5 Gy (SF5) irradiation of cells from wild-type U87 xenografts. In contrast, induction of RhoBN19 in U87RhoBN19 xenografts by dexamethasone resulted in a significant reduction in clonogenicity after 5 Gy irradiation (Po0.01) (Figure 1b ). This demonstrated that the expression of RhoBN19 is able to induce a radiosensitization of U87RhoBN19 xenografts in vivo as it does in vitro . We then compared the radiosensitizer effect of RhoBN19 expression when expressed in vitro and in vivo. The decrease of SF5 value of U87 xenografts after RhoBN19 expression was more important in vivo than in vitro (57.376.8 versus 35.078.9%, Po0.05) (data not shown), suggesting that the in vivo increase of the radiosensitizer effect could be due to a regulation of the microenvironment. We then determined the effect of RhoBN19 expression on tumor oxygenation.
RhoBN19 expression induces an oxygenation of U87RhoBN19 xenografts
For studying the hypothesis that RhoBN19 expression could control the oxygenation of this tumor, we first compared the oxygenation status of U87RhoBN19 xenografts after induction or not of RhoBN19 by dexamethasone. Mice bearing U87RhoBN19 or U87 xenografts were treated with dexamethasone during 6 days at the same concentration as the one used for the clonogenic assay, and hypoxia was evaluated by fluorescent antibody staining for EF5 bound to tumor cells. U87 xenografts presented large regions of hypoxia even after treatment with dexamethasone (Figure 2a and b) as well as U87RhoBN19 xenografts in the absence of Rho dominant negative induction (Figure 2c) . However, when RhoBN19 expression was induced by dexamethasone in U87RhoBN19 xenografts, hypoxic regions of the tumor disappeared (Figure 2d ). Quantitative analysis of the presence of hypoxia was performed by determining the exposure time necessary for obtaining the same intensity of EF5 signal on photography. The exposure time presented a 3.8770.47-fold increase after induction of RhoBN19 (Po0.001). This result demonstrates that the expression of RhoBN19 induces a significant increase of the oxygenation in U87RhoBN19 xenografts.
RhoBN19 expression induces a migration of the U87 cells along the vessels
Since oxygenation status has been related to the distance between tumor cells and the vessels, we first compared the tissue organization in U87 xenografts after induction or not of RhoBN19 expression. No change was (Figure 3a) , whereas tumor cells were homogeneously dispersed in the non-induced RhoBN19 xenografts (Figure 3b ). This change in tumor architecture could in part explain the oxygenation observed after RhoBN19 expression.
RhoBN19 expression reduces vessel density
To analyse if this oxygenation effect of RhoBN19 expression might also be associated with a change in tumor vasculature, we examined the vessel morphology by immunohistochemistry using an anti-CD31 antibody in all tumors that have been examined for the oxygenation status. As already described (Wolff et al., 1997) , dexamethasone alone inhibited the vessel density (Figure 4a and b) . Non-induced RhoBN19 tumors showed a more heterogeneously distributed vascular network with more elongated and branched vessel structures as shown in Figure 4c . However, after induction by dexamethasone of RhoBN19 in U87RhoBN19 xenografts, vessel structures were more homogeneously distributed in the tumors and the vessels appeared smaller than the vessels in the control tumors (Figure 4d) . We quantified the vessel density by quantifying, after immnunohistochemistry, the ratio of the anti-CD31-stained surface versus the total surface of the slice (Figure 4e ). Dexamethasone treatment alone significantly reduced the vessel density (Po0.01). However, the reduction of vessel density induced by RhoBN19 was significantly more important than the one obtained after dexamethasone treatment (Po0.001). These data demonstrate that Rho controls the tumor angiogenesis in U87 xenografts.
RhoBN19 expression decreases MMP2 expression and activity
Tumor angiogenesis is dependent on the expression of different factors including enzymes implicated in proteolytic modifications of extracellular matrix like metalloproteinases. Matrix metalloproteinases (MMPs), particularly MMP-2 (Itoh et al., 1998) , are implicated in angiogenesis, owing to their ability to digest basement membrane collagens. We first analysed the level of MMP2 in U87RhoBN19 xenografts after induction or not of RhoBN19. Dexamethasone alone did not modify the expression of MMP2 in U87 xenografts (Figure 5a and b). In contrast, RhoBN19 expression induced an evident decrease of MMP2 level in U87 xenografts (Figure 5c and d) . We then studied the gelatinase activity of MMP-2 in U87 cells after induction or not of RhoBN19 by zymography. As shown in Figure 5e , while dexamethasone did not change MMP2 activity in U87 cells, RhoBN19 expression induced a dramatic decrease in MMP-2 activity. Taken together, these results strongly suggest that Rho might control angiogenesis via MMP-2 expression in U87 cells.
Discussion
In a previous study, we demonstrated that Rho was involved in the radioresistance pathway of U87 glioblastoma cell line and that it could be the target of the radiosensitizing effect of FTI in this cell line . We showed in this study that in vivo expression of RhoBN19 led to the radiosensitization of radioresistant human glioblastoma xenografts. Furthermore, this in vivo radiosensitizer effect of RhoBN19 was greater than the in vitro one, indicating that RhoBN19 expression might have an effect on tumor microenvironment. Since hypoxia is an important component of tumor radioresistance, we investigated the role of Rho pathway inhibition on tumor oxygenation. We demonstrated here that expressing RhoBN19 in U87 human glioblastoma xenografts expressing wild-type Ras induced a significant oxygenation of these tumors. Recent studies have demonstrated that small GTPases RhoA, Cdc42 and, Rac1, but not RhoB, expression was induced in vitro during hypoxia in renal cell carcinoma by reactive oxygen species. Treating these cells with C3-exoenzyme that inhibits RhoA, B and C leads to the inhibition of the signal cellular cascade induced by hypoxia, suggesting that Rho proteins seem to be the regulators of this pathway (Turcotte et al., 2003) . Our present results strongly suggest that Rho pathways, probably RhoB, could be involved in the regulation of the tumor oxygenation pathway in glioma.
Tumor oxygenation can also be due to the regulation of angiogenesis. Antiangiogenic agents such as AGM-1470 (Bernsen et al., 1998) , anti-VEGF antibodies (Kim et al., 1993) or suramin (Bernsen et al., 1999) in human glioblastoma xenografts are able to induce an increase of the oxygenation status associated with an induction of a change in the vessel morphology. In these conditions of treatment, the vessels appear thinner and more homogeneously distributed within the tumor (Bernsen et al., 1999) , although other authors described a decrease in vascular density after antiangiogenic therapies (Yuan et al., 1996) . Our experiments show that induction of RhoBN19 in U87 xenografts induced a , has already been described either in the control of the migration of endothelial cells (Uchida et al., 2000; Paik et al., 2001) or in the control of the production of angiogenic factors (van Golen et al., 2000) . Our results are in agreement with other observations that have reported an increase in the radiosensitivity of antiangiogenic-treated tumors based on an increase of the tumor perfusion and oxygenation (Teicher et al., 1995; Kakeji and Teicher, 1997; Nozue et al., 1997) . Moreover, the histological analysis of the glioma xenografts revealed that, in the xenografts of animals treated with dexamethasone, U87RhoBN19 cells migrated along the vessels and then remained closer to the vessel structures than tumor cells of the non-induced U87RhoBN19 xenografts. This modification of tumor architecture may also contribute to a better oxygenation. This migration of glioma cells along the vessels, called vessel co-option, has already been described very recently in an orthotopic glioma model (Kunkel et al., 2001) . In response to antiangiogenic therapy, glioma cells can co-opt pre-existent cerebral vessels to provide blood supply (Holash et al., 1999 ). Our results demonstrate that inhibiting Rho pathways in glioma xenograft modifies the structure and the organization of tumor vasculature in glioma xenografts. As angiogenesis requires proteolytic modifications of the extracellular matrix by metalloproteinases, we compared the expression of MMP2 in U87 and U87RhoBN19 xenografts and demonstrated that RhoBN19 expression reduces the level of MMP2 expression. Moreover, the in vitro induction of RhoBN19 led to an inhibition of MMP-2 activity. The small GTPase Rac1 has also been implicated in angiogenesis by activating MMP2 in fibrosarcoma cell lines (Zhuge and Xu, 2001) . In contrast, the treatment of non-tumor cells like human T-lymphocyte cell lines (Esparza et al., 1999) or bovine smooth muscle cells (Koike et al., 2000) by Rho inhibitory C3 toxin leads to an increase in MMP2 activity, suggesting that Rho We show here that a Rho protein, probably RhoB, is involved in the control of different factors leading to in vivo radioresistance in glioblastoma xenografts. RhoB might not only control intrinsic radioresistance of glioblastoma and angiogenesis, but also hypoxia of these highly aggressive and radioresistant tumors. Our results suggest, for the first time, the existence of a common pathway regulated by a Rho protein, probably RhoB, that controls different mechanisms involved in tumor radioresistance. Specific inhibition of RhoB could be an important therapeutic weapon as an adjuvant treatment combined with radiotherapy in glioblastoma, to improve the response of this tumor to treatment.
